Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 47, Issue 1, 2006, Pages 111-115

  Gutiérrez, Antonio ^a   Rodríguez, José ^b   Martínez, Jordi ^a   Amezaga, Rocío ^a   Ramos, Rafael ^a   Galmes, Bernat ^a   Bea, Maria Dolores ^a   Ferrer, Joana ^a   Pons, Jaume ^a   Sampol, Antonia ^a   Morey, Miguel ^a   Duran, María Antonia ^a   Raurich, Joan ^a   Besalduch, Joan ^a  

^a University Hospital 'San Dureta'   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Complement; Cytokine; Lymphoma; Rituximab; Shock; Toxicity

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; B CELL LYMPHOMA; BLOOD SAMPLING; BRONCHOSPASM; CANCER STAGING; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG FATALITY; DRUG INDUCED DISEASE; FEMALE; HUMAN; LARGE CELL LYMPHOMA; LUNG INSUFFICIENCY; MALE; PRIORITY JOURNAL; SHOCK;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CYTOKINES; FATAL OUTCOME; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; RISK FACTORS; SHOCK; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 30844442400     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500254752     Document Type: Article

References (19)

1. Coiffier, B and Haioun, C and Ketterer, N and Engert, A and Tilly, H and Ma, D and (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study Blood, 92, pp. 1927 - 1932.
2. Vose, J and Link, B and Grossbard, M and Czuczman, M and Grillo-Lopez, A and Gilman, P and (2001) Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma J Clin Oncol, 19, pp. 389 - 397.
3. Coiffier, B and Lepage, E and Briere, J and Herbrecht, R and Tilly, H and Bouabdallah, R and (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med, 346, pp. 235 - 242.
4. Byrd, J and Waselenko, J and Maneatis, T and Murphy, T and Ward, F and Monahan, B and (1999) Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance J Clin Oncol, 17, pp. 791 - 795.
5. Winkler, U and Jensen, M and Manzke, O and Schulz, H and Diehl, V and Engert, A. (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8) Blood, 94, pp. 2217 - 2224.
6. Lim, L and Koh, L and Tan, P. (1999) Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia J Clin Oncol, 17, pp. 1962 - 1963.
7. Kunzmann, V and Ruediger, T and Hallek, M and Mueller-Hermelink, H and Wilhelm, M. (2001) Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment Blood, 98, pp. 1991 - 1992.
8. van der Kolk, L and Grillo-Lopez, A and Baars, J and Hack, C and van Oers, M. (2001) Complement activation plays a key role in the side-effects of rituximab treatment Br J Haematol, 115, pp. 807 - 811.
9. Matolcsy, A and Chadburn, A and Knowles, D. (1995) De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct Am J Pathol, 147, pp. 207 - 216.
10. Yamaguchi, M and Seto, M and Okamoto, M and Ichinohasama, R and Nakamura, N and Yoshino, T and (2002) De novo CD5+ diffuse large B-cell lymphoma: A clinicopathologic study of 109 patients Blood, 99, pp. 815 - 821.
11. Bogdan, C and Vodovotz, Y and Nathan, C. (1991) Macrophage deactivation by interleukin 10 J Exp Med, 174, pp. 1549 - 1555.
12. Levy, Y and Brouet, J. (1994) Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein J Clin Invest, 93, pp. 424 - 428.
13. Oberholzer, A and Oberholzer, C and Moldawer, L. (2000) Cytokine signaling - regulation of the immune response in normal and critically ill states Crit Care Med, 28(Suppl 4), pp. N3 - N12.
14. Oberholzer, A and Oberholzer, C and Moldawer, L. (2002) Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug Crit Care Med, 30(1 Suppl 1), pp. S58 - S63.
15. Wing, M and Moreau, T and Greenwood, J and Smith, R and Hale, G and Isaacs, J and (1996) Mechanism of first-dose cytokine - release syndrome by CAMPATH 1-H: Involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells J Clin Invest, 98, pp. 2819 - 2826.
16. Bienvenu, J and Chvetzoff, R and Salles, G and Balter, C and Tilly, H and Herbrecht, R and (2001) Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment Hematol J, 2, pp. 378 - 384.
17. Marty, C and Misset, B and Tamion, F and Fitting, C and Carlet, J and Cavaillon, J. (1994) Circulating interleukin-8 concentrations in patients with multiple organ failure of septic and nonseptic origin Crit Care Med, 22, pp. 673 - 679.
18. Miller, E and Cohen, A and Nagao, S and Griffith, D and Maunder, R and Martin, T and (1992) Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality Am Rev Respir Dis, 146, pp. 427 - 432.
19. Damas, P and Canivet, J and de Groote, D and Vrindts, Y and Albert, A and Franchimont, P and (1997) Sepsis and serum cytokine concentrations Crit Care Med, 25, pp. 405 - 412.